Harmony Biosciences Holdings, Inc. (HRMY) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time, please press star zero and a member of our team will be happy to help. so so ¶¶ ¶¶ ¶¶ ¶¶ Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time, please press star zero, and a member of our team will be happy to help. ¶¶ . . . ¶¶ Good morning. My name is Angela, and I will be your conference operator today. At this time, I would like to welcome everyone to Harmony Bioscience's fourth quarter and full year 2025 financial results conference call. All participant lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question at that time, please press star one on your telephone keypad. Please be advised that today's conference may be recorded. Lastly, if you should require operator assistance, please press star zero. I will now turn the call over to Matthew Beck from Aster Partners. Please go ahead. Thank you, operator. Good morning, everyone, and thank you for joining us today as we review Harmony Bioscience's fourth quarter 2025 financial results and provide a business update. Before we start, I encourage everyone to go to the investor section of our website to find the materials that accompany our discussion today, including a reconciliation of our GAAP to non-GAAP financial measures. At this stage of our lifecycle, we believe the non-GAAP financial results better represent the underlying business performance. Our speakers on today's call are Dr. Jeffrey Dano, President and CEO, Adam Zeske, Chief Commercial Officer, Dr. Kumar Bajor, Chief Medical and Scientific Officer, and Sandeep Kapadia, Chief Finan...